Novartis offers to buy rest of Chiron

Article Abstract:

Novartis AG of Switzerland has offered to acquire Chiron Corp. of the United States for $4.5 billion. The Swiss pharmaceutical giant already owns 42 percent of the beleaguered United States biotechnology company and has offered to acquire the rest of the company for $40 per share.

---

Novartis agrees to acquire the rest of Chiron for $5.1 billion

Article Abstract:

Novartis AG of Switzerland is to acquire the remaining stake in Chiron Corp. of the United States for $5.1 billion. The pharmaceutical giant already owned 42 percent of the biotechnology company and is planning to turn around the vaccine business.

---

Biotech industry heads toward IPO boomlet

Article Abstract:

Several biotechnology firms are planning to hold initial public offerings (IPOs), after being previously skeptical about the IPO market. However, analysts are raising concerns about the quality of the planned IPOs.

Strategy & planning, Biological Product (except Diagnostic) Manufacturing, Securities issued, listed, Molecular Biological Products, Planning, Biotechnology industry, Biotechnology industries, Securities, Specialty chemicals, Going public (Securities), Initial public offerings, Company securities, Company public offering, Biotechnology, Company business planning

Similar abstracts:

• Abstracts: Vivendi would sell assets to save Bertelsmann deal. Vivendi agrees to buy BMG for $2.1 billion, besting rivals
• Abstracts: Banks cut ties to North Korea. North Korea agrees to give up nuclear arms
• Abstracts: British Petroleum to acquire Amoco in $48.2 billion deal. U.N council nears Iraq resolution
• Abstracts: Volkswagen aims to triple U.S. sales. Volkswagen sees additional gains in profit, revenue. VW launches redesigned Golf

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.